What is Retatrutide? The UK Guide to the World's Most Powerful Weight Loss Drug

If you've ended up here, you're likely wondering what it is, whether it actually works, and whether you can get it in the UK. This guide answers all three.

What is Retatrutide?

Retatrutide (also known by its research code LY3437943) is a next-generation weight loss compound developed by Eli Lilly — the same pharmaceutical company behind Mounjaro.

Where Ozempic targets a single receptor (GLP-1), and Mounjaro targets two (GLP-1 and GIP), Retatrutide hits three: GLP-1, GIP, and glucagon. That triple mechanism is why researchers call it a "triple agonist" — and it's why the results are unlike anything that's come before it.

In plain terms: it's the most powerful metabolic drug ever put through clinical trials.

How does it work?

To understand why Retatrutide is such a leap forward, you need to understand what each receptor does:

GLP-1 (Glucagon-like peptide-1)

This is the hormone that tells your brain you're full and slows down digestion. It's the mechanism that makes Ozempic work. When activated, you simply stop feeling hungry the way you used to.

GIP (Glucose-dependent insulinotropic polypeptide)

GIP enhances the GLP-1 effect — amplifying appetite suppression and improving insulin sensitivity. Adding GIP is why Mounjaro outperforms Ozempic.

Glucagon

Here's what makes Retatrutide different. Glucagon directly increases energy expenditure — your body burns more calories, even at rest. It also targets visceral fat (the dangerous fat stored around your organs) specifically. No other approved weight loss drug does this.

The combination of all three creates a compounding effect: less appetite, better insulin response, and a metabolism that's actively burning more energy. That third mechanism is what no approved weight loss drug currently offers, and it's the strongest argument for Retatrutide — stronger, honestly, than the headline percentage.

What do the clinical trials show?

Retatrutide's Phase 3 programme runs under the name TRIUMPH-1 (trial registration NCT05929066). On 21 May 2026, Eli Lilly announced the topline results from 2,339 participants.

That "highest dose" part matters, and most coverage skips it. TRIUMPH-1 tested three doses, and the results scale with the dose:

All three figures are measured at 80 weeks — not one year. That's a year and a half of weekly injections, which is worth knowing before you measure yourself against the headline.

Two further results are worth having. In the 12mg group, 45.3% of participants lost 30% or more of their body weight — territory previously associated with bariatric surgery. And in a pre-specified extension of 532 participants with a starting BMI of 35 or above, average loss reached 30.3% at 104 weeks.

The earlier Phase 2 trial (Jastreboff et al., published in the New England Journal of Medicine in June 2023, 338 participants) showed 24.2% at 48 weeks on the 12mg dose. The Phase 3 numbers are consistent with it.

To put the top-line figure alongside its predecessors:

• Ozempic / Wegovy (semaglutide 2.4mg): ~15% — STEP-1, 68 weeks
• Mounjaro (tirzepatide 15mg): ~21–27% — SURMOUNT-1 through SURMOUNT-4, 72 to 88 weeks
• Retatrutide 12mg: 28.3% — TRIUMPH-1, 80 weeks

One caveat on that comparison, because nobody else seems to make it: these figures come from separate trials with different durations, and they treat drop-outs differently. The 28.3% is what's called an efficacy estimand — it measures people who stayed on the drug. Lined up properly, Retatrutide's lead over the best Mounjaro results is real but narrower than a straight reading suggests: a couple of percentage points, not a chasm.

It is still the most effective weight loss compound yet taken through a Phase 3 obesity trial. It just isn't magic, and the gap over what's already on prescription is smaller than the headlines imply.

Is Retatrutide approved in the UK?

Not yet. As of July 2026, Retatrutide has not been approved by the MHRA (the UK medicines regulator) and cannot be legally prescribed or dispensed in the UK.

Lilly has not published a submission timeline, and I'm not going to invent one. What can be said is that TRIUMPH-1 met its endpoints in May 2026, that further results were due at the American Diabetes Association Scientific Sessions, and that the path from a successful Phase 3 to a UK prescription has historically taken years rather than months. If it follows Wegovy and Mounjaro, early access would be restricted to specialist clinics and specific patient criteria rather than being generally available.

That means if you want to access it now, the only route is through research peptide suppliers.

How are people in the UK accessing it now?

Retatrutide exists in what researchers call a "legal grey area." It is not a licensed medicine, not a controlled drug, and not on any UK banned import list. It's sold by specialist peptide suppliers — typically from China — as a research compound.

The "for research use only" label these suppliers use is a legal disclaimer. The reality is that thousands of people in the UK are already using it.

The typical process involves:

1. Sourcing lyophilised (freeze-dried) Retatrutide powder in vials from a reputable supplier
2. Reconstituting with bacteriostatic water
3. Injecting weekly using either a reusable peptide pen or insulin syringes

Each of those steps is more awkward to describe than it is to do. The whole process — sterile technique, the reconstitution arithmetic, transferring to a cartridge — is written up in the step-by-step guide to mixing and injecting Retatrutide.

It's more involved than loading an Ozempic pen — but the cost difference is stark. A private UK clinic prescribing Mounjaro charges £199–359 a month depending on your dose. I paid £168.63 for 200mg, delivered — that's £0.84 per milligram, and roughly a year's supply at a typical 4mg maintenance dose. Bought as a single 200mg kit rather than two of 100mg it would have been £140. Full costs, to the penny, are on the resources page.

That's the tradeoff: more hands-on, significantly cheaper, dramatically more powerful.

How does it compare to Mounjaro and Ozempic?

The gap over Ozempic is large and consistent. The gap over Mounjaro is real but modest — a few percentage points at the top dose, and it disappears entirely if you compare Mounjaro's best results against Retatrutide at 4mg. Anyone telling you Retatrutide leaves Mounjaro standing is quoting the top of one trial against the middle of another.

The stronger arguments for it, honestly, are the third mechanism and the cost — not a step-change in the headline number.

What are the side effects?

The side effect profile is broadly similar to Mounjaro and Ozempic, with some key differences:

Common (especially in the first 4–6 weeks)

• Nausea
• Reduced appetite (this is the intended effect, but it can feel uncomfortable early on)
• Constipation
• Fatigue

Less common

• Vomiting
• Mild headache
• Dizziness

Retatrutide vs Mounjaro on side effects: Retatrutide tends to cause stronger initial side effects, particularly nausea in the first month. The glucagon component increases this. This is why starting at the lowest possible dose and titrating slowly is not optional — it's essential.

The good news: most people find that side effects reduce significantly after weeks 4–6 as the body adapts. The appetite suppression remains; the nausea largely doesn't.

What's the dosing protocol?

Do not rush this. The temptation to jump to a higher dose to accelerate results is understandable — resist it. The titration schedule exists specifically to minimise side effects and let your body adjust. Most people find 4mg/week is the sweet spot for long-term maintenance.

That table is the short version. The 12-month protocol sets the same titration out week by week alongside the Phase 3 dose-response figures, and works through what each scenario comes to in vials and in pounds.

My take

I'm not a doctor, a pharmacist, or a researcher. I'm someone who spent weeks researching this, decided Retatrutide was the most rational choice given the clinical data, and started documenting the journey publicly so others don't have to piece it together alone. The prologue is the version with the reasons in it — what I weighed, what finally made me act, and why I landed on this compound rather than a clinic.

The clinical evidence for Retatrutide is genuinely strong — up to 28.3% at the top dose in Phase 3 is not hype. But it's a number attached to a specific dose over a specific 80 weeks, and it gets quoted everywhere with both of those stripped off. Read it with the conditions attached and it's still the best result any obesity drug has produced. Read it as a promise and you'll be disappointed.

Whether you choose to access it now via the research route or wait for MHRA approval, being informed about what it is and how it works puts you ahead of most people walking into a GP's office asking for "the weight loss jab."

That's what this site is for.